Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA)

BACKGROUND: Reduction of cyclin-dependent kinase inhibitor 2A (CDKN2A) (p16 and p14) expression through DNA methylation has been reported in prostate cancer (PCa). This meta-analysis was conducted to assess the difference of p16 and p14 methylation between PCa and different histological types of non...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Zipei, Wei, Lijuan, Zhu, Weizhi, Yao, Xuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
7300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895353/
https://www.ncbi.nlm.nih.gov/pubmed/29561434
http://dx.doi.org/10.1097/MD.0000000000010182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895353/
https://www.ncbi.nlm.nih.gov/pubmed/29561434
http://dx.doi.org/10.1097/MD.0000000000010182

Ejemplares similares